Veru (NASDAQ:VERU) Shares Up 9.8%

Veru Inc (NASDAQ:VERU)’s share price shot up 9.8% on Wednesday . The stock traded as high as $2.01 and last traded at $2.01, 232,447 shares changed hands during mid-day trading. An increase of 4% from the average session volume of 222,632 shares. The stock had previously closed at $1.83.

Several brokerages have weighed in on VERU. ValuEngine upgraded shares of Veru from a “hold” rating to a “buy” rating in a research note on Friday, May 10th. Zacks Investment Research cut shares of Veru from a “hold” rating to a “sell” rating in a research note on Wednesday. Cantor Fitzgerald began coverage on shares of Veru in a research note on Monday, July 1st. They issued an “overweight” rating and a $6.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $4.50 price objective on shares of Veru in a research note on Friday, August 9th. Finally, Brookline Capital Management began coverage on shares of Veru in a research note on Monday, July 29th. They issued a “buy” rating and a $12.00 price objective for the company. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $5.71.

The firm’s 50-day moving average price is $2.17 and its 200 day moving average price is $1.74. The company has a market capitalization of $130.73 million, a price-to-earnings ratio of -5.15 and a beta of 0.37. The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.13.

Veru (NASDAQ:VERU) last issued its earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). The company had revenue of $9.73 million during the quarter, compared to analysts’ expectations of $8.11 million. Veru had a negative net margin of 59.68% and a negative return on equity of 50.14%. As a group, equities research analysts anticipate that Veru Inc will post -0.18 earnings per share for the current fiscal year.

In other news, insider Mitchell Shuster Steiner sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $1.98, for a total value of $39,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 70,000 shares of company stock valued at $152,400 over the last 90 days. Corporate insiders own 29.50% of the company’s stock.

Several large investors have recently modified their holdings of VERU. Virtu Financial LLC bought a new stake in shares of Veru during the 1st quarter valued at approximately $95,000. BlackRock Inc. grew its holdings in shares of Veru by 9.3% during the 4th quarter. BlackRock Inc. now owns 128,766 shares of the company’s stock valued at $180,000 after purchasing an additional 10,956 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Veru by 115.4% during the 4th quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock valued at $301,000 after purchasing an additional 115,506 shares during the last quarter. Wedge Capital Management L L P NC bought a new stake in shares of Veru during the 2nd quarter valued at approximately $394,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Veru by 183.1% during the 2nd quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock valued at $558,000 after purchasing an additional 169,550 shares during the last quarter. Institutional investors own 9.20% of the company’s stock.

Veru Company Profile (NASDAQ:VERU)

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Further Reading: Options Trading – Understanding Strike Price

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.